Dimension, I haven't been able to find any companies working on clinical trials for SQ injection. Testosterone gel will go generic before QST is on the market so thats going to be the biggest challenge. The gel costs around $500 a month now but the price will probably be cut in half. $500 for QST or $250 for the gel is a tough sell.
I'm still waiting for the buy-out that Matscum predicted when Howarth was hired. Matscum was wrong on most of his calls about the stock but his pump worked.
You can recover all your losses if you just double your position. If the stock goes to $1 then double it again. Works every time.
Are you dumb?
What does that have to do with the US filing?
This is a portion of a LOKO post. " look at Disposable Pen #1....Launch date.... 9/30/2015..... which again fits for Egranli....... tbo-filgrastim has taken longer to get to market then one would imagine. As many know, I have posting on it for years, and nailed the drug, but failed miserably on the date. And there is a second Pen #1 is for Lonquex (lipegfilgrastim) and shows it is in P3....which is correct.."
•Sandoz is the first company to announce it has filed for approval of a biologic under the biosimilars pathway created in the Biologics Price Competition and Innovation Act of 2009 (BPCIA)
More lousy news for our TEVA partnership.
if they raised $50 million at $2 then ATRS would be a buy. There is to much uncertainty with Otrexup & Medac so they need to raise funds to insure funding for QST's development.
The last time this trading pattern occurred the fund that was exiting bought back in at lower prices on a secondary.
Just listen to the August/13th investor update. This is the type of CEO you can believe in.
just for the epi-syringe. Most epi-pens are stored in case of emergency & expire before use. It makes more sense for a lot of individuals to just store a basic pre-filled syringe. Its cheaper & if you need it in an emergency situation then the pre-filled syringe works as well as a injector.
a epinephrine pre-filled syringe which will compete against the epi-pen. (Poor mans version of the epi-pen) They also have a number of other products in development with a market cap of $50 million.